Bio Techne Company Top Insiders
TECH Stock | USD 62.16 2.28 3.81% |
Bio Techne employs about 3.1 K people. The company is managed by 24 executives with a total tenure of roughly 42 years, averaging almost 1.0 years of service per executive, having 129.17 employees per reported executive. Assessment of Bio Techne's management performance can provide insight into the firm performance.
Charles Kummeth CEO CEO and President and Director |
Bio |
Bio Techne Management Team Effectiveness
The company has return on total asset (ROA) of 0.0568 % which means that it generated a profit of $0.0568 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0783 %, meaning that it created $0.0783 on every $100 dollars invested by stockholders. Bio Techne's management efficiency ratios could be used to measure how well Bio Techne manages its routine affairs as well as how well it operates its assets and liabilities.Bio Techne Workforce Comparison
Bio Techne Corp is rated third in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 31,558. Bio Techne holds roughly 3,100 in number of employees claiming about 10% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.13 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.18 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.18. Bio Techne Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Techne insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Techne's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bio Techne insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Herr Amy E. over two weeks ago Insider Trading | ||
Herr Amy E. over three weeks ago Disposition of 1976 shares by Herr Amy E. of Bio Techne at 44.33 subject to Rule 16b-3 | ||
Kim Kelderman over a month ago Disposition of 13392 shares by Kim Kelderman of Bio Techne at 37.7 subject to Rule 16b-3 | ||
Kim Kelderman over six months ago Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3 | ||
Kim Kelderman over six months ago Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3 | ||
Klimovsky Judith V over six months ago Insider Trading | ||
Harold Wiens over a year ago Bio Techne exotic insider transaction detected | ||
Rupert Vessey over a year ago Acquisition by Rupert Vessey of 1625 shares of Bio Techne subject to Rule 16b-3 |
Bio Techne Notable Stakeholders
A Bio Techne stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bio Techne often face trade-offs trying to please all of them. Bio Techne's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bio Techne's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Charles Kummeth | CEO and President and Director | Profile | |
MD MBA | President Genomics | Profile | |
William Geist | President Segment | Profile | |
James CPA | Executive CFO | Profile | |
James Hippel | CFO and VP of Fin. | Profile | |
Gary Latham | VP CTO | Profile | |
Robert Gavin | Sr. VP of Protein Platforms Division | Profile | |
Shane Bohnen | General VP | Profile | |
Lynne Hohlfeld | Senior Division | Profile | |
Luca Cicchetti | Managing Director | Profile | |
Brenda JD | Gen VP | Profile | |
Martin Wirtz | Senior Development | Profile | |
Cheryl Bethune | Senior Officer | Profile | |
David CFA | Senior Development | Profile | |
Gerry Andros | Vice Marketing | Profile | |
Bernie Andruss | Senior Division | Profile | |
Kim Kelderman | Pres Genomics | Profile | |
Evett Kruka | Senior Division | Profile | |
Dylan Malayter | Senior Division | Profile | |
David Clair | IR Contact Officer | Profile | |
Kevin Smyth | Senior Officer | Profile | |
Steven Silverman | Senior Experience | Profile | |
Brenda Everson | Senior Officer | Profile | |
Steve Crouse | Senior Division | Profile |
About Bio Techne Management Performance
The success or failure of an entity such as Bio Techne Corp often depends on how effective the management is. Bio Techne management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota. Bio-Techne operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3000 people.
Bio Techne Workforce Analysis
Traditionally, organizations such as Bio Techne use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bio Techne within its industry.Bio Techne Manpower Efficiency
Return on Bio Techne Manpower
Revenue Per Employee | 373.9K | |
Revenue Per Executive | 48.3M | |
Net Income Per Employee | 54.2K | |
Net Income Per Executive | 7M | |
Working Capital Per Employee | 147.8K | |
Working Capital Per Executive | 19.1M |
Complementary Tools for Bio Stock analysis
When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories |